Skip to main content
This R&D Website is for US Healthcare Professionals Only

Pipeline

Explore Our Pipeline

AbbVie has been involved in oncology research, discovery and development for more than 20 years. Our team members combine their deep understanding of cancer with state-of-the-art technologies to research, validate and target specific molecular pathways. This allows us to discover and develop innovative therapies that aim to disturb the natural progression of cancer cells.

Investigational drugs mentioned are for use in clinical studies only, and may be studied alone or in combination with drugs for indications that have not been approved by the FDA. Approved drugs mentioned are also being studied for uses for which they are not approved. Safety and efficacy have not been established for any of these drugs for the uses being studied.

AbbVie in no way intends to recommend or imply that these drugs should be used for unapproved uses.

View Cancer Type

Hematologic Malignancies

Phase 1

Phase 2

Phase 3

Approved

Elotuzumab

Overview

Elotuzumab is a humanized monoclonal antibody (hMAb) targeting signaling lymphocytic activation molecule family member 7 (SLAMF7), a cell surface glycoprotein that is highly and uniformly expressed on myeloma cells, but is minimally expressed on normal cells.1-3

Proposed Mechanism of Action

In preclinical cell line models, elotuzumab exerted anti-MM activity via natural killer (NK) cell mediated antibody-dependent cell-mediated cytotoxicity (ADCC).1,3

Development

AbbVie and Bristol-Myers Squibb received approval from the US Food and Drug Administration (FDA) for elotuzumab in combination with lenalidomide and dexamethasone for the treatment of patients with MM who have received 1 to 3 prior therapies. AbbVie continues to conduct ongoing clinical trials to better understand this compound's role in the treatment of MM.

Clinical Trials

View select clinical trials with elotuzumab now. To view a full list of clinical trials in which elotuzumab is being investigated, please visit ClinicalTrials.gov.

Elotuzumab is being studied for uses that are not approved. Safety and efficacy have not been established for these uses.

Close
Multiple Myeloma (MM) Treatment Naïve
PH 3
Multiple Myeloma (MM)
App.

Ibrutinib

Overview

The recent acquisition of Pharmacyclics and its lead product complements AbbVie's mission in oncology. Ibrutinib is a small molecule inhibitor of Bruton's tyrosine kinase (BTK).4,5

Proposed Mechanism of Action

BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways that is important for the development and activity of B cells.6-8 Ibrutinib inhibits BTK enzymatic activity by forming a covalent bond in the active catalytic site.4,5,9 Inhibiting BTK disables the activation of B cells by disturbing and interrupting the signaling and activation pathways necessary for B-cell differentiation and proliferation.5

Development

Ibrutinib represents a “pipeline in a product,” with significant growth potential through its existing and expanding list of indications and potential acceleration in treatment protocols. Specifically, ibrutinib is currently being evaluated in more than 50 clinical trials (16 of which are in phase 3) as a potential treatment option for several additional hematological cancers.

Clinical Trials

View select clinical trials with ibrutinib now. To view a full list of clinical trials in which ibrutinib is being investigated, please visit ClinicalTrials.gov.

Ibrutinib is being studied for uses that are not approved. Safety and efficacy have not been established for these uses.

Close
Chronic Lymphocytic Leukemia (CLL)
App.
Mantle Cell Lymphoma (MCL)
App.
Waldenström's Macroglobulinemia (WM)
App.
Marginal Zone Lymphoma (MZL)
Ph 3
Diffuse Large B-Cell Lymphoma (DLBCL)
PH 2
Follicular Lymphoma (FL)
PH 2
Multiple Myeloma (MM)
PH 2
Acute Myeloid Leukemia (AML)
PH 2
Acute Lymphoblastic Leukemia (ALL)
PH 2

Venetoclax

Overview

Venetoclax is a selective, orally bioavailable small-molecule BCL-2 inhibitor.10

Proposed Mechanism of Disease

The BCL-2 protein binds and sequesters proapoptotic proteins, limiting their ability to initiate apoptosis. Venetoclax is designed to bind to BCL-2, preventing it from binding to proapoptotic proteins and thereby restoring the cell's ability to undergo apoptosis.10

Development

Venetoclax was approved in April 2016 under accelerated approval conditions for the treatment of patients with CLL with 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy. AbbVie and Genentech continue to investigate venetoclax in ongoing phase 3 and phase 2 clinical trials for the treatment of CLL, as well as a variety of other cancers, including NHL, AML, follicular lymphoma, Waldenström's macroglobulinemia (WM) and diffuse large B-cell lymphoma (DLBCL).

Clinical Trials

View select clinical trials with venetoclax now. To view a full list of clinical trials in which venetoclax is being investigated, please visit ClinicalTrials.gov.

Venetoclax is being studied for uses that are not approved. Safety and efficacy have not been established for these uses.

MOD and PROPOSED MOA

See the role of the BCL-2 pathway in evading apoptosis and promoting tumor survival.

Close
Chronic Lymphocytic Leukemia (CLL) with 17p deletion
App.
Chronic Lymphocytic Leukemia (CLL)
PH 3
Non-Hodgkin Lymphoma (NHL)
PH 2
Acute Myeloid Leukemia (AML)
PH 1
Multiple Myeloma (MM)
PH 1

ABBV-838

Overview

ABBV-838 is a signaling lymphocytic activation molecule family member 7 (SLAMF7)-targeted antibody-drug conjugate (ADC).

Development

AbbVie is investigating ABBV-838 in a phase 1 clinical trial for the treatment of multiple myeloma (MM).

Clinical Trials

To view a full list of clinical trials in which ABBV-838 is being investigated, please visit ClinicalTrials.gov.

ABBV-838 is an investigational drug for clinical study only. Safety and Efficacy has not been established.

Close
Multiple Myeloma (MM)
PH 1

ABBV-075

Development

ABBV-075 is a small molecule Bromodomain and Extra-Terminal motif (BET) inhibitor being studied in a phase 1 clinical trial in patients with advanced hematologic malignancies and solid tumors.

Clinical Trials

To view a full list of clinical trials in which ABBV-075 is being investigated, please visit ClinicalTrials.gov.

ABBV-075 is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Acute Myeloid Leukemia (AML)
PH 1
Multiple Myeloma (MM)
PH 1

Lung Cancer

Phase 1

Phase 2

Phase 3

Approved

Veliparib

Overview

Veliparib is an oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor AbbVie is evaluating in multiple tumor types.11,12

Proposed Mechanism of Action

Proteins of the PARP family are naturally occurring enzymes in human cells that are critical to the repair of single-strand DNA breaks.11,12 While this is a useful process to maintain the integrity of healthy cells, the same process can also repair chemotherapy-induced DNA damage in cancer cells that may have limited capacity for repairing double-strand DNA breaks.12,13 Veliparib is designed to inhibit PARP1 and PARP2, potentially leading to the accumulation of single-strand and double-strand DNA breaks in tumor cells that may have limited capacity for DNA repair, which results in chromosomal instability, cell cycle arrest, and subsequent apoptosis.11,12,14

Development

Veliparib is being developed in settings where it can be combined with common DNA-damaging therapies like chemotherapy or radiation.11,12,15-18 It is in clinical trials for the treatment of patients with triple-negative breast cancer (TNBC) and NSCLC, as well as a number of other cancer types.

Clinical Trials

View select clinical trials with veliparib now. To view a full list of clinical trials in which veliparib is beinginvestigated, please visitClinicalTrials.gov.

Veliparib is an investigational drug that is for clinical study only. Safety and efficacy have not been established.

MOD and Proposed MOA

See how veliparib may play a role in dual PARP inhibition.

Close
Squamous Non-Small Cell Lung Cancer (sqNSCLC)
PH 3
Non-Squamous Non-Small Cell Lung Cancer (NsqNSCLC)
PH 3
Small Cell Lung Cancer (SCLC)
PH 1

Rovalpituzumab Tesirine

Overview

Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate (ADC) comprised of an anti-DLL3 antibody conjugated to a pyrrolobenzodiazepine dimer (PBD), a sequence selective DNA cross linking agent.19

Proposed Mechanism of Action

DLL3 is expressed at high levels on the cell surface of >80% of small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) tumors but not in normal adult tissues.19 In pre-clinical models, Rova-T has been shown to specifically bind to DLL3, followed by internalization and trafficking to late endosomes. The cytotoxin (PBD) is released, ultimately leading to apoptosis of the tumor cell with minimal effect on normal tissue. In preclinical animal models, observed toxicities were attributed to off-target toxicity of the linked cytotoxin.19

Development

Rova-T is currently being investigated in phase 1 and phase 2 trials for the treatment of SCLC, LCNEC, and other advanced solid tumors. Rova-T has received orphan drug designation from the FDA for treatment of SCLC.

Clinical Trials

View select clinical trials with Rova-T now. To view a full list of clinical trials in which Rova-T is being investigated, please visit ClinicalTrials.gov.

Rovalpituzumab tesirine is an investigational drug for clinical study only. Safety and Efficacy have not been established.

MOD and Proposed MOA

Learn more about rovalpituzumab tesirene, an antibody-drug conjugate.

Close
Small Cell Lung Cancer (SCLC)
PH 2

Brain Cancer

Phase 1

Phase 2

Phase 3

Approved

ABT-414

Overview

ABT-414 is an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC).20

Proposed Mechanism of Action

ABT-414 is an antibody-drug conjugate (ADC) that combines the cytotoxin monomethyl auristatin F (MMAF) with a monoclonal antibody targeting a unique tumor-specific epitope of the EGFR that exhibits minimal reactivity to EGFR in normal tissues.20 As an ADC, ABT-414 is designed to remain stable in the bloodstream, potentially releasing the potent cytotoxin only inside targeted cancer cells. Studies are being conducted to determine if this approach can potentially reduce the toxic side effects of traditional chemotherapy while enhancing antitumor activity.

Development

ABT-414 is currently being investigated in phase 1/2 trials for the treatment of glioblastoma, the most common and most aggressive malignant primary brain tumor. ABT-414 is also in clinical trials for the treatment of patients with squamous cell tumors.

Clinical Trials

View select clinical trials with ABT-414 now. To view a full list of clinical trials in which ABT-414 is being investigated, please visit ClinicalTrials.gov.

ABT-414 is an investigational drug that is for clinical study only. Safety and efficacy have not been established.

MOD and Proposed MOA

Learn about EGFR amplification and mutation.

Close
Glioblastoma (GBM)
PH 2

Breast Cancer

Phase 1

Phase 2

Phase 3

Approved

Veliparib

Overview

Veliparib is an oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor AbbVie is evaluating in multiple tumor types.11,12

Proposed Mechanism of Action

Proteins of the PARP family are naturally occurring enzymes in human cells that are critical to the repair of single-strand DNA breaks.11,12 While this is a useful process to maintain the integrity of healthy cells, the same process can also repair chemotherapy-induced DNA damage in cancer cells that may have limited capacity for repairing double-strand DNA breaks.12,13 Veliparib is designed to inhibit PARP1 and PARP2, potentially leading to the accumulation of single-strand and double-strand DNA breaks in tumor cells that may have limited capacity for DNA repair, which results in chromosomal instability, cell cycle arrest, and subsequent apoptosis.11,12,14

Development

Veliparib is being developed in settings where it can be combined with common DNA-damaging therapies like chemotherapy or radiation.11,12,15-18 It is in clinical trials for the treatment of patients with triple-negative breast cancer (TNBC) and NSCLC, as well as a number of other cancer types.

Clinical Trials

View select clinical trials with veliparib now. To view a full list of clinical trials in which veliparib is beinginvestigated, please visitClinicalTrials.gov.

Veliparib is an investigational drug that is for clinical study only. Safety and efficacy have not been established.

MOD and Proposed MOA

See how veliparib may play a role in dual PARP inhibition.

Close
Triple Negative Breast Cancer (TNBC)
PH 3
Breast Cancer (BRCA)
PH 3

Solid Tumors

Phase 1

Phase 2

Phase 3

Approved

Ibrutinib

Overview

The recent acquisition of Pharmacyclics and its lead product complements AbbVie's mission in oncology. Ibrutinib is a small molecule inhibitor of Bruton's tyrosine kinase (BTK).4,5

Proposed Mechanism of Action

BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways that is critically important for the development and activity of B cells.6-8 Ibrutinib inhibits BTK enzymatic activity by forming a covalent bond in the active catalytic site.4,5,9 Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.5

Development

Ibrutinib represents a “pipeline in a product,” with significant growth potential through its existing and expanding list of indications and potential acceleration in treatment protocols. Specifically, ibrutinib is currently being evaluated in more than 50 clinical trials (16 of which are in phase 3) as a potential treatment option for several additional hematological cancers.

Clinical Trials

View select clinical trials with ibrutinib now. To view a full list of clinical trials in which ibrutinib is being investigated, please visit ClinicalTrials.gov.

ibrutinib is being studied for uses that are not approved. Safety and efficacy have not been established for these uses.

Close
Solid Tumors
PH 1

Veliparib

Overview

Veliparib is an oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor AbbVie is evaluating in multiple tumor types.11,12

Proposed Mechanism of Action

Proteins of the PARP family are naturally occurring enzymes in human cells that are critical to the repair of single-strand DNA breaks.11,12 While this is a useful process to maintain the integrity of healthy cells, the same process can also repair chemotherapy-induced DNA damage in cancer cells that may have limited capacity for repairing double-strand DNA breaks.12,13 Veliparib is designed to inhibit PARP1 and PARP2, potentially leading to the accumulation of single-strand and double-strand DNA breaks in tumor cells that may have limited capacity for DNA repair, which results in chromosomal instability, cell cycle arrest, and subsequent apoptosis.11,12,14

Development

Veliparib is being developed in settings where it can be combined with common DNA-damaging therapies like chemotherapy or radiation.11,12,15-18 It is in clinical trials for the treatment of patients with triple-negative breast cancer (TNBC) and NSCLC, as well as a number of other cancer types.

Clinical Trials

View select clinical trials with veliparib now. To view a full list of clinical trials in which veliparib is being investigated, please visit ClinicalTrials.gov.

Veliparib is an investigational drug that is for clinical study only. Safety and efficacy have not been established.

MOD and PROPOSED MOA

See how veliparib may play a role in dual PARP inhibition.

Close
Ovarian Cancer
PH 3
Colorectal Cancer
PH 2

ABBV-221

Overview

ABBV-221 is an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC).

Proposed Mechanism of Action

ABBV-221 is our second-generation EGFR ADC that has three important distinctions from ABT-414. First, it contains an affinity matured antibody (ABT-806 AM1) with a higher affinity for EGFR. Second, it utilizes a linker that allows for bystander effect (valine-citrulline). Third, it utilizes the cytotoxin monomethyl auristatin E (MMAE) that should be as potent to tumor cells as MMAF, yet limits any ocular toxicity. ABBV-221 is thought to remain stable in the bloodstream, potentially releasing the potent chemotherapy agent only inside targeted cancer cells. Studies are being conducted to determine if this approach could help reduce the toxic side effects of traditional chemotherapy while potentially enhancing antitumor activity.

Development

Being developed by AbbVie researchers, ABBV-221 is currently being investigated in a phase 1 study for the treatment of EGFR-expressing solid tumors.

Clinical Trials

View select clinical trials with ABBV-221 now. To view a full list of clinical trials in which ABBV-221 is being investigated, please visit ClinicalTrials.gov.

ABBV-221 is an investigational drug for clinical study only. Safety and Efficacy have not been established.

Close
Solid Tumors
PH 1

ABBV-399

Overview

ABBV-399 is a c-Met targeted antibody-drug conjugate (ADC).

Development

ABBV-399 is being studied in a phase 1 clinical trial in patients with solid tumors.

Clinical Trials

To view a full list of clinical trials in which ABBV-399 is being investigated, please visit ClinicalTrials.gov.

ABBV-399 is an investigational drug for clinical study only. Safety and Efficacy have not been established.

Close
Solid Tumors
PH 1

ABBV-085

Development

ABBV-085 is being studied in a phase I clinical trial in patients with advanced solid tumors.

Clinical Trials

To view a full list of clinical trials in which ABBV-085 is being investigated, please visit ClinicalTrials.gov.

ABBV-085 is an investigational drug for clinical study only. Safety and Efficacy have not been established.

Close
Advanced Solid Tumors
PH 1

ABT-767

Overview

ABT-767 is a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor.

Development

ABT-767 is being investigated in an ongoing phase 1 clinical trial in patients with a variety of solid tumors.

Clinical Trials

View select clinical trials with ABT-767 now. To view a full list of clinical trials in which ABT-767 is being investigated, please visit ClinicalTrials.gov.

ABT-767 is an investigational drug for clinical study only. Safety and Efficacy have not been established.

MOD and Proposed MOA

See how the PARP-mediated DNA repair pathway promotes tumor cell survival.

Close
Solid Tumors
PH 1

ABT-414

Overview

ABT-414 is an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC).20

To view a full list of clinical trials in which ABT-414 is being investigated, please visit ClinicalTrials.gov.

ABT-414 is an investigational drug for clinical study only. Safety and Efficacy have not been established.

Close
Solid Tumors
PH 1

ABT-165

Overview

ABT-165 is a dual variable domain immunoglobulin (DVD-Ig) that inhibits both DLL4 and VEGF.21

Development

ABT-165 is being studied in phase 1 trials for the treatment of patients with advanced solid tumors.

Clinical Trials

View select clinical trials with ABT-165 now. To view a full list of clinical trials in which ABT-165 is being investigated, please visit ClinicalTrials.gov.

ABT-165 is an investigational drug for clinical study only. Safety and Efficacy have not been established.

Close
Solid Tumors
PH 1

ABBV-075

Development

ABBV-075 is a small molecule Bromodomain and Extra-Terminal motif (BET) inhibitor being studied in a phase I clinical trial in patients with advanced hematologic malignancies and solid tumors.

Clinical Trials

View select clinical trials with ABBV-075 now. To view a full list of clinical trials in which ABBV-075 is being investigated, please visit ClinicalTrials.gov.

ABBV-075 is an investigational drug for clinical study only. Safety and Efficacy have not been established.

Close
Solid Tumors
PH 1

Rovalpituzumab Tesirine

Overview

Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate (ADC) comprised of an anti-DLL3 antibody conjugated to a pyrrolobenzodiazepine dimer (PBD), a sequence selective DNA cross linking agent.19

Proposed Mechanism of Action

DLL3 is expressed at high levels on the cell surface of >80% of small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) tumors but not in normal adult tissues.19 In pre-clinical models, Rova-T has been shown to specifically bind to DLL3, followed by internalization and trafficking to late endosomes. The cytotoxin (PBD) is released, ultimately leading to apoptosis of the tumor cell with minimal effect on normal tissue. In preclinical animal models, observed toxicities were attributed to off-target toxicity of the linked cytotoxin.19

Development

Rova-T is currently being investigated in phase 1 and phase 2 trials for the treatment of SCLC, LCNEC, and other advanced solid tumors. Rova-T has received orphan drug designation from the FDA for treatment of SCLC.

Clinical Trials

View select clinical trials with Rova-T now. To view a full list of clinical trials in which Rova-T is being investigated, please visit ClinicalTrials.gov.

Rovalpituzumab tesirine is an investigational drug for clinical study only. Safety and Efficacy have not been established.

MOD and Proposed MOA

Learn more about rovalpituzumab tesirene, an antibody-drug conjugate.

Close
Advanced Solid Tumors
PH 1

References

  1. Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008 15;112(4):1329-1337.
  2. Tai YT, Anderson KC. Antibody-based therapies in multiple myeloma. Bone Marrow Res. 2011;2011:924058.
  3. Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775-2784.
  4. Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem. 2007;2(1):58-61.
  5. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075-13080.
  6. Xia B, Qu F, Yuan T, Zhang Y. Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies. Oncol Lett. 2015;10(6):3339-3344.
  7. Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6:59.
  8. Maas A, Hendriks RW. Role of Bruton's tyrosine kinase in B cell development. Dev Immunol. 2001;8(3-4):171-181.
  9. Chang BY, Francesco M, De Rooij MF, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122(14):2412-2424.
  10. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-208.
  11. Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13(9):2728-2737.
  12. Palma JP, Wang YC, Rodriguez LE, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res. 2009;15(23):7277-7290.
  13. Anders CK, Winer EP, Ford JM, et al. Poly(ADP-Ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer. Clin Cancer Res. 2010;16(19):4702-4710.
  14. Plummer ER, Calvert H. Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy. Clin Cancer Res. 2007;13(21):6252-6256.
  15. Owonikoko TK, Zhang G, Deng X, et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med. 2014;3(6):1579-1594.
  16. Cheng H, Zhang Z, Borczuk A, et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis. 2013;34(4):739-749.
  17. Kummar S, Wade JL, Oza AM, et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Invest New Drugs. 2016 Mar 21. [Epub ahead of print]
  18. Reiss KA, Herman JM, Zahurak M, et al. A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. Clin Cancer Res. 2015;21(1):68-76.
  19. Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7(302):302ra136.
  20. Phillips AC, Boghaert ER, Vaidya KS, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther. 2016 Feb 4. [Epub ahead of print]
  21. Li Y, Hickson J, Ambrosi D, et al. ABT-165 is a first-in-class therapeutic Dual Variable Domain Immunoglobulin (DVD-IgTM) that targets DLL4 and VEGF for the treatment of cancer. Proceedings of the AACR, Part A: Abstracts 1-2696. 2016;57:abstract 867.